Fenofibrate in Ulcerative Colitis
Inflammatory Bowel Diseases
About this trial
This is an interventional treatment trial for Inflammatory Bowel Diseases
Eligibility Criteria
Inclusion Criteria: Age ≥ 18 years Both males and females will be included Negative pregnancy test and effective contraception. Mild and moderate UC patients diagnosed and confirmed by an endoscope Exclusion Criteria: Breastfeeding Significant liver and kidney function abnormalities Colorectal cancer patients Other inflammatory bowel diseases (CD). Patients with severe UC Patients taking rectal or systemic steroids Patients taking immunosuppressives or biological therapies Addiction to alcohol and/or drugs Known allergy to the Fenofibrate
Sites / Locations
- Tanta UnuversityRecruiting
Arms of the Study
Arm 1
Arm 2
Active Comparator
Active Comparator
Control Group
Fenofibrate group
Mesalamine group will receive 1 g mesalamine three times daily for 6 months
Fenofibrate group will receive 1 g mesalamine three times daily plus Fenofibrate (160 mg/day) for 6 months